Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease-A randomized placebo-controlled study

Atherosclerosis

Volumn 196, Issue 1, 2008, Pages 434-442

  Fernandes, Juliano Lara ^a   de Oliveira, Romulo Tadeu Dias ^b   Mamoni, Ronei Luciano ^b   Coelho, Otavio Rizzi ^b   Nicolau, Jose Carlos ^a   Blotta, Maria Heloisa S L ^b   Serrano Jr , Carlos Vicente ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Atherosclerosis; Coronary disease; Immunology; Inflammation; Pentoxifylline

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; HEPARIN; INTERLEUKIN 12; INTERLEUKIN 6; PENTOXIFYLLINE; PLACEBO; TIROFIBAN; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; DRUG ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; IMMUNOMODULATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ACUTE CORONARY SYNDROME; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INFLAMMATION; INTERFERON TYPE II; INTERLEUKINS; MALE; MIDDLE AGED; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38049079202     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.11.032     Document Type: Article

References (30)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
2. Frostegard J., Ulfgren A.K., Nyberg P., et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145 (1999) 33-43
3. Zhou X., Paulsson G., Stemme S., et al. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 101 (1998) 1717-1725
4. Uyemura K., Demer L.L., Castle S.C., et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 97 (1996) 2130-2138
5. Fernandes J.L., Mamoni R.L., Orford J.L., et al. Increased Th1 activity in patients with coronary artery disease. Cytokine 26 (2004) 131-137
6. Liuzzo G., Vallejo A.N., Kopecky S.L., et al. Molecular fingerprint of interferon-gamma signaling in unstable angina. Circulation 103 (2001) 1509-1514
7. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331 (1994) 417-424
8. Biasucci L.M., Vitelli A., Liuzzo G., et al. Elevated levels of interleukin-6 in unstable angina. Circulation 94 (1996) 874-877
9. Pinderski Oslund L.J., Hedrick C.C., Olvera T., et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 19 (1999) 2847-2853
10. Grainger D.J. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 24 (2004) 399-404
11. Cipollone F., Fazia M., Mincione G., et al. Increased expression of transforming growth factor-beta1 as a stabilizing factor in human atherosclerotic plaques. Stroke 35 (2004) 2253-2257
12. Mallat Z., and Tedgui A. The role of transforming growth factor beta in atherosclerosis: novel insights and future perspectives. Curr Opin Lipidol 13 (2002) 523-529
13. Lutgens E., Cleutjens K.B., Heeneman S., et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA 97 (2000) 7464-7469
14. Zhao L., Cuff C.A., Moss E., et al. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J Biol Chem 277 (2002) 35350-35356
15. Laurat E., Poirier B., Tupin E., et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 104 (2001) 197-202
16. Ramani M., Khechai F., Ollivier V., et al. Interleukin-10 and pentoxifylline inhibit C-reactive protein-induced tissue factor gene expression in peripheral human blood monocytes. FEBS Lett 356 (1994) 86-88
17. D'Hellencourt C.L., Diaw L., Cornillet P., et al. Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline. Int J Immunopharmacol 18 (1996) 739-748
18. Ward A., and Clissold S.P. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34 (1987) 50-97
19. Sliwa K., Woodiwiss A., Kone V.N., et al. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 109 (2004) 750-755
20. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
21. Bhatt D.L., and Topol E.J. Need to test the arterial inflammation hypothesis. Circulation 106 (2002) 136-140
22. Belloc F., Jaloustre C., Dumain P., et al. Effect of pentoxifylline on apoptosis of cultured cells. J Cardiovasc Pharmacol 25 Suppl. 2 (1995) S71-S74
23. Neuner P., Klosner G., Schauer E., et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 83 (1994) 262-267
24. Boldt J., Brosch C., Lehmann A., et al. Prophylactic use of pentoxifylline on inflammation in elderly cardiac surgery patients. Ann Thorac Surg 71 (2001) 1524-1529
25. Boldt J., Brosch C., Piper S.N., et al. Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. Crit Care Med 29 (2001) 952-958
26. Benagiano M., Azzurri A., Ciervo A., et al. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci USA 100 (2003) 6658-6663
27. Gupta S., Pablo A.M., Jiang X., et al. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 99 (1997) 2752-2761
28. Terkeltaub R.A. IL-10: an "immunologic scalpel" for atherosclerosis?. Arterioscler Thromb Vasc Biol 19 (1999) 2823-2825
29. Heeschen C., Dimmeler S., Hamm C.W., et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 107 (2003) 2109-2114
30. Bogaty P., Brophy J.M., Noel M., et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. Circulation 110 (2004) 934-939